About Arranta Bio
Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. It was founded in 2019 and is based in Watertown, Massachusetts. On February 18th, 2022, Arranta Bio was acquired by Recipharm. Terms of the transaction were not disclosed.
Latest Arranta Bio News
Jun 19, 2023
News provided by Share this article Share this article This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global biologics contract development market is expected to grow from $6.27 billion in 2022 to $7.00 billion in 2023 at a compound annual growth rate (CAGR) of 11.61%. The biologics contract development market is expected to reach $10.29 billion in 2027 at a CAGR of 10.13%. Major players in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc., LakePharma Inc., GenScript, Bionova Scientific Inc., Boehringer Ingelheim BioXcellence, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, and Forge Biologics. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Biologics contract development refers to companies that provide biologics development and manufacturing services to pharmaceutical corporations on a contract basis. The biologics contract development is used to outsource the manufacturing of biologics on contracts to focus on the marketing, R&D, and branding of products. The main source of biologics contract development are microbial, mammalian, and others soruces. The microbial source of biologics contract development are used for the production of various biologics. The biologics contract development indication are oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others indications that are applied in the product service of biologics contract development such as cell line development, process development, and others product services. Technological advancements are gaining popularity in the biologics contract development market. Major companies in the biologics contract development market are integrating advanced technologies to sustain their position in the market. For instance, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, launched bYlok technology platform to design and manufacture bispecific antibodies. It helps to solve the light-heavy chain mispairing issue with high yields, >95% accuracy, and the ability to maintain a mAb-like format. It can be accessed by pharma and biotech companies through a simple research license. In February 2022, Recipharm, a Sweden-based pharmaceutical contract development and manufacturing organization, acquired Vibalogics and Arranta Bio for an undisclosed amount. This acquisition will strengthen Recipharm's presence in advanced therapy medicinal products and enable it to expand virotherapy manufacturing capabilities in the US. Vibalogics is a Germany-based contract development and manufacturing organization. Arranta Bio is a US-based contract development and manufacturing organization. North America was the largest region in the biologics contract development market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biologics contract development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The rising prevalence of chronic diseases is expected to propel the biologics contract development market going forward. Chronic diseases refer to an illness that lasts for a year or longer that requires ongoing medical attention. The rise in chronic disease cases is increasing the demand for developing novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, according to data published in April 2021 by the World Health Organization, a Switzerland-based health organization for international public health, 41 million people die every year due to chronic diseases globally, close to 71% of all deaths. Therefore, the rising prevalence of chronic diseases will drive the biologics contract development market. The biologics contract development market includes revenues earned by entities by sourcing, solid and specialized formulation development, and process analytics development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. Key Topics Covered: 3. Biologics Contract Development Market Trends And Strategies 4. Biologics Contract Development Market - Macro Economic Scenario 4.1. COVID-19 Impact On Biologics Contract Development Market 4.2. Ukraine-Russia War Impact On Biologics Contract Development Market 4.3. Impact Of High Inflation On Biologics Contract Development Market 5. Biologics Contract Development Market Size And Growth 5.1. Global Biologics Contract Development Historic Market, 2017-2022, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Biologics Contract Development Forecast Market, 2022-2027F, 2032F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Biologics Contract Development Market Segmentation 6.1. Global Biologics Contract Development Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Microbial
Arranta Bio Frequently Asked Questions (FAQ)
When was Arranta Bio founded?
Arranta Bio was founded in 2019.
Where is Arranta Bio's headquarters?
Arranta Bio's headquarters is located at 650 Pleasant Street, Watertown.
What is Arranta Bio's latest funding round?
Arranta Bio's latest funding round is Acquired.
How much did Arranta Bio raise?
Arranta Bio raised a total of $82M.
Who are the investors of Arranta Bio?
Investors of Arranta Bio include Recipharm, Thermo Fisher Scientific and Ampersand Capital Partners.